{
  "id": "602356b81cb411341a000099",
  "type": "factoid",
  "question": "Tofersen has been developed for treatment of which disease?",
  "ideal_answer": "Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis is being studied for the treatment of amyotrophic lateral sclerosis due to SOD1 mutations.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32640130",
    "http://www.ncbi.nlm.nih.gov/pubmed/34704267"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.METHODS: We conducted a phase 1-2 ascending-dose trial evaluating tofersen in adults with ALS due to SOD1 mutations. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32640130",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32640130",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.METHODS: We conducted a ph",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32640130",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to S",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32640130",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ently, the results of a phase I/II study using the antisense oligonucleotides Tofersen to treat familial amyotrophic lateral sclerosis with superoxide dismutase 1 mutation have been reported. In",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34704267",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " synthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32640130",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, the results of a phase I/II study using the antisense oligonucleotides Tofersen to treat familial amyotrophic lateral sclerosis with superoxide dismutase 1 mutation have been reported.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34704267",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " mutations.METHODS: We conducted a phase 1-2 ascending-dose trial evaluating tofersen in adults with ALS du",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32640130",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " synthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.METHODS: We conducted a phase 1-2 ascending-dose trial evaluating tofersen in adults with ALS d",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32640130",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "amyotrophic lateral sclerosis"
}